EpiBiologics
Updated: March 27, 2026
CEO - Ann Lee-Karlon
Country: USA | Funding: $203.1M (+)
Founded: 2022
Website: https://www.epibiologics.com/
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
Founded: 2022
Website: https://www.epibiologics.com/
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
